Tag: KRAS inhibitor combination

Home / KRAS inhibitor combination

Categories

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

  June 2024: The Food and Drug Administration has given accelerated approval to adagrasib (Krazati; Mirati Therapeutics, Inc.) in combination with cetuximab for adults who have KRAS G12C-mutat...
kras-inhibitor-combination

Scan the code